Investor Relations

Investor Relations

Dec 13 4:30 PM EST Dec 13, 2021 | 4:30 PM EST
Regeneron Investor Event, ASH 2021

Dec 6 2:00 PM EST Dec 6, 2021 | 2:00 PM EST
H.C. Wainwright & Co. – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam’s RNAi Platform Collaboration Update

Dec 1 8:00 AM EST Dec 1, 2021 | 8:00 AM EST
Piper Sandler 33rd Annual Healthcare Conference

btn Events

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in nine FDA-approved medicines and numerous product candidates in a range of diseases, including blindness-causing eye diseases, severe inflammatory conditions like asthma and atopic dermatitis, hematologic conditions, pain and infectious diseases such as Ebola and COVID-19.

Analyst Center


Analyst Center

Interactive and downloadable financial data for investors and analysts

btn Analyst Center

Contact us

Investor Relations


Media Relations

Email Alerts

IR Tools